Combining Venetoclax with chemotherapy for treating acute myeloid leukemia and advanced MDS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1b clinical trial evaluates the safety and tolerability of Venetoclax in combination with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia (AML) and advanced myelodysplastic syndromes (MDS). The study consists of two parts: a dose escalation phase to determine the maximum tolerated dose (MTD) of the drug combination, followed by a dose expansion phase to further assess safety and efficacy. Patients will be monitored for various response parameters, including overall survival and event-free survival, as well as the eradication of leukemia stem cells. The trial aims to provide insights into the effectiveness of this combination therapy in treating these aggressive blood cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* New diagnosis of AML by WHO criteria. Patients with higher risk MDS (R-IPSS\>3.5) and 10% blasts or more, or proliferative (WBC ≥ 13 x 10⁹/L) CMML-2 are also eligible at the discretion of the PI. Patients having received any prior hypomethylating agent with or without BCL2 inhibitor therapy for MDS/AML are also eligible at the discretion of the PI
* Patients ≥ 18 to ≤ 75 years.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
* Adequate renal function including creatinine clearance \> 30 mL/min based on the Cockcroft Gault equation.
* Adequate hepatic function including total bilirubin \< 1.5x ULN unless increase is due to Gilbert's disease or leukemic involvement, and AST and/or ALT \< 3x ULN unless considered due to leukemic involvement
* Ability to understand and provide signed informed consent
* Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug.

Exclusion Criteria:

* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (FAB class M3-AML)
* Subject has known active CNS involvement with AML
* Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF \<45% by echocardiogram or multi-gated acquisition (MUGA) scan
* Patients with a history of myocardial infarction within the last 6 months or unstable / uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias
* Patients with uncontrolled infection with human immunodeficiency virus (HIV) or active Hepatitis B or C
* Patients with known dysphagia, short-gut syndrome, or other conditions that would affect the ingestion or gastrointestinal absorption of drugs administered orally.
* Subject has any other significant medical or psychiatric history that in the opinion of the investigator would adversely affect participation in this study.
* Subject has a white blood cell count \> 25 x 10⁹/L. (Note: Hydroxyurea and/or cytarabine (up to 2 g/m\^2 is permitted to meet this criterion.)
* Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception. Appropriate method(s) of contraception include oral or injectable hormonal birth control, IUD, and double barrier methods (for example a condom in combination with a spermicide).

Where it's running

• Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM)
  The Bronx, New York, United States Recruiting

Study contacts

• Principal investigator: Ioannis Mantzaris, MD — Montefiore Medical Center
• Study coordinator: Ioannis Mantzaris, MD
• Email: imantzar@montefiore.org
• Phone: 718-920-4826

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• CD33-armed immune cell treatment for adults with MRD-positive AML or MDS

  This treatment will try giving adults with MRD-positive AML or MDS infusions of their own T cells coated with a CD33-directed bispecific antibody together with standard hypomethylating therapy (and possibly venetoclax) to see if it is safe and lowers residual disease.

  Recruiting Phase 1 University of Virginia · Charlottesville, Virginia · NCT07270978

• Venetoclax-enhanced BUCY versus standard BUCY conditioning for high‑risk AML and MDS before allogeneic stem cell transplant

  This will test whether adding venetoclax to BUCY conditioning before allogeneic stem cell transplant helps patients aged 12–60 with high‑risk AML or MDS stay in remission longer.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07183878

• Blood transfusions at home

  This pilot tests whether giving required blood transfusions at home works well and is acceptable for adults with transfusion-dependent blood cancers or bone marrow failure who receive care at SKCCC.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07121140

• Adding decitabine and venetoclax to fludarabine/melphalan reduced‑intensity transplant for myeloid cancers

  This study tests whether giving decitabine and venetoclax around a reduced‑intensity allogeneic transplant is safe for adults with high‑risk acute myeloid leukemia or myelodysplastic syndromes.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT07044544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.